Literature DB >> 18287094

Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells.

Efstratios Katsoulidis1, Antonella Sassano, Beata Majchrzak-Kita, Nathalie Carayol, Patrick Yoon, Alison Jordan, Brian J Druker, Eleanor N Fish, Leonidas C Platanias.   

Abstract

The interferons (IFNs) are cytokines that play key roles in host defense against viral infections and immune surveillance against cancer. We report that BCR-ABL transformation of hematopoietic cells results in suppression of IFN-dependent responses, including transcription of IFN-inducible genes and generation of IFN-mediated antiviral effects. BCR-ABL transformation suppresses expression of several IFN-regulated genes containing IFN-sensitive response element (ISRE) or GAS elements in their promoters, including Isg15, Irf1, Irf9, and Ifit2 (interferon-induced protein with tetratricopeptide repeats 2). Suppression of transcription of ISRE-containing genes is also seen in cells expressing various BCR-ABL kinase domain mutants, including T315I, H396P, Y253F, and E255K, but not kinase-defective BCR-ABL. Such effects are associated with impaired IFN-dependent phosphorylation of Stat1 on Tyr(701) and Stat3 on Tyr(705) and defective binding of Stat complexes to ISRE or GAS elements. Beyond suppression of Stat activities, BCR-ABL inhibits IFN-inducible phosphorylation/activation of the p38 MAPK, suggesting a dual mechanism by which this abnormal fusion protein blocks IFN transcriptional responses. The inhibitory activities of BCR-ABL ultimately result in impaired IFNalpha-mediated protection against encephalomyocarditis virus infection and reversal of IFN-dependent growth suppression. Altogether, our data provide evidence for a novel mechanism by which BCR-ABL impairs host defenses and promotes malignant transformation, involving dual suppression of IFN-activated signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18287094      PMCID: PMC2447623          DOI: 10.1074/jbc.M706816200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  73 in total

Review 1.  Viruses and interferon: a fight for supremacy.

Authors:  Michael G Katze; Yupeng He; Michael Gale
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

2.  Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.

Authors:  Ian J Griswold; Mary MacPartlin; Thomas Bumm; Valerie L Goss; Thomas O'Hare; Kimberly A Lee; Amie S Corbin; Eric P Stoffregen; Caitlyn Smith; Kara Johnson; Erika M Moseson; Lisa J Wood; Roberto D Polakiewicz; Brian J Druker; Michael W Deininger
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

Review 3.  Interferons and their actions.

Authors:  S Pestka; J A Langer; K C Zoon; C E Samuel
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

4.  Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.

Authors:  Simrit Parmar; Efstratios Katsoulidis; Amit Verma; Yongzhong Li; Antonella Sassano; Lakhvir Lal; Beata Majchrzak; Farhad Ravandi; Martin S Tallman; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2004-03-31       Impact factor: 5.157

Review 5.  ISG15: the immunological kin of ubiquitin.

Authors:  Kenneth J Ritchie; Dong-Er Zhang
Journal:  Semin Cell Dev Biol       Date:  2004-04       Impact factor: 7.727

6.  Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.

Authors:  Pandurangan Ramaraj; Harjeet Singh; Ning Niu; Su Chu; Melissa Holtz; Jiing Kuan Yee; Ravi Bhatia
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

7.  The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.

Authors:  Y Ben-Neriah; G Q Daley; A M Mes-Masson; O N Witte; D Baltimore
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

8.  Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells.

Authors:  Ikuya Sakai; Kazuto Takeuchi; Hayato Yamauchi; Hirosi Narumi; Shigeru Fujita
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

9.  Low expression of interferon regulatory factor-1 and identification of novel exons skipping in patients with chronic myeloid leukaemia.

Authors:  Dimitrios Tzoanopoulos; Matthaios Speletas; Konstantinos Arvanitidis; Christina Veiopoulou; Sofia Kyriaki; George Thyphronitis; Paschalis Sideras; Georgios Kartalis; Konstantinos Ritis
Journal:  Br J Haematol       Date:  2002-10       Impact factor: 6.998

10.  Engagement of protein kinase C-theta in interferon signaling in T-cells.

Authors:  Kishore K Srivastava; Sandeep Batra; Antonella Sassano; Yongzhong Li; Beata Majchrzak; Hiroaki Kiyokawa; Amnon Altman; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2004-05-18       Impact factor: 5.157

View more
  11 in total

1.  Curcumin induces apoptosis in human leukemic cell lines through an IFIT2-dependent pathway.

Authors:  Yonglu Zhang; Yunyuan Kong; Shuyuan Liu; Lingbing Zeng; Lagen Wan; Zhanglin Zhang
Journal:  Cancer Biol Ther       Date:  2017-01-10       Impact factor: 4.742

2.  Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor.

Authors:  Sabyasachi Bhattacharya; Hui Zheng; Christos Tzimas; Martin Carroll; Darren P Baker; Serge Y Fuchs
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

Review 3.  Interferon-stimulated gene 15 and the protein ISGylation system.

Authors:  Dongxian Zhang; Dong-Er Zhang
Journal:  J Interferon Cytokine Res       Date:  2010-12-29       Impact factor: 2.607

4.  Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.

Authors:  Monique Hinchcliff; Chiang-Ching Huang; Wataru Ishida; Feng Fang; Jungwha Lee; Nadareh Jafari; Mark Wilkes; Swati Bhattacharyya; Edward Leof; John Varga
Journal:  Clin Exp Rheumatol       Date:  2012-05-29       Impact factor: 4.473

Review 5.  Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes.

Authors:  Eleanor N Fish; Leonidas C Platanias
Journal:  Mol Cancer Res       Date:  2014-09-12       Impact factor: 5.852

Review 6.  Deregulation of Interferon Signaling in Malignant Cells.

Authors:  Efstratios Katsoulidis; Surinder Kaur; Leonidas C Platanias
Journal:  Pharmaceuticals (Basel)       Date:  2010-02-04

7.  The Effector TepP Mediates Recruitment and Activation of Phosphoinositide 3-Kinase on Early Chlamydia trachomatis Vacuoles.

Authors:  Victoria Carpenter; Yi-Shan Chen; Lee Dolat; Raphael H Valdivia
Journal:  mSphere       Date:  2017-07-19       Impact factor: 4.389

8.  SHP2 is required for BCR-ABL1-induced hematologic neoplasia.

Authors:  S Gu; A Sayad; G Chan; W Yang; Z Lu; C Virtanen; R A Van Etten; B G Neel
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528

9.  Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha.

Authors:  Claudia Schubert; Manuel Allhoff; Stefan Tillmann; Tiago Maié; Ivan G Costa; Daniel B Lipka; Mirle Schemionek; Kristina Feldberg; Julian Baumeister; Tim H Brümmendorf; Nicolas Chatain; Steffen Koschmieder
Journal:  J Hematol Oncol       Date:  2019-04-02       Impact factor: 17.388

10.  Importin-7 mediates nuclear trafficking of DNA in mammalian cells.

Authors:  Arjun Dhanoya; Tse Wang; Eli Keshavarz-Moore; Ariberto Fassati; Benjamin M Chain
Journal:  Traffic       Date:  2012-11-07       Impact factor: 6.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.